ABIVAX Société Anonyme (ABVX)Healthcare | Biotechnology | Paris, France | NasdaqGM
86.22 USD
-0.72
(-0.828%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 86.02 -0.20 (-0.200%) ⇩ (Oct. 13, 2026, 6:29 p.m. EDT) |
Hot Take ↕ | Oct. 3, 2026, 1:33 a.m. EDT
Abivax presents a classic biotech dilemma: massive recent gains contrast sharply with current technical weakness. The stock has surged 715% over the past year, yet it is now trading below both its 50-day and 200-day moving averages, indicating a correction phase. While analysts project a $164 target, implying substantial upside, the fundamentals remain fragile with negative earnings and a price-to-sales ratio exceeding 1700 times. There is no dividend income to cushion the downside. Options flow reveals aggressive bullish positioning at higher strikes, suggesting traders expect a recovery, but the recent price action suggests the market is absorbing negative trial updates. The long-term outlook remains neutral because the security has too little price history to assess long-term trends reliably, while the short-term view leans slightly bearish given the technical breakdown. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.093186 |
| MSTL | 0.101004 |
| AutoETS | 0.102297 |
| AutoTheta | 0.165554 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 52.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.035 |
| Excess Kurtosis | 0.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.331 |
| Revenue per Share | 0.06 |
| Market Cap | 7,524,551,168 |
| Forward P/E | -22.21 |
| Beta | -0.23 |
| Website | https://www.abivax.com |
As of Oct. 3, 2026, 1:33 a.m. EDT: Call option open interest significantly outweighs put open interest across most expirations, with heavy positioning at strikes 150 to 200. Deep out-of-the-money calls show inflated implied volatility, suggesting speculation on a massive upside move. Put activity is concentrated at lower strikes (65-85), indicating downside hedging or contrarian bets, but the overall gamma exposure favors upside.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.0906809 |
| Address1 | 7-11 Boulevard Haussmann |
| All Time High | 148.83 |
| All Time Low | 4.77 |
| Ask | 119.33 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,227,530 |
| Average Daily Volume3 Month | 1,111,876 |
| Average Volume | 1,111,876 |
| Average Volume10Days | 1,227,530 |
| Beta | -0.232 |
| Bid | 121.16 |
| Bid Size | 1 |
| Book Value | 5.1400013 |
| City | Paris |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 86.22 |
| Current Ratio | 5.965 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 86.845 |
| Day Low | 84.51 |
| Debt To Equity | 0.331 |
| Display Name | ABIVAX |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,712,579,400 |
| Earnings Call Timestamp Start | 1,712,579,400 |
| Earnings Timestamp | 1,790,020,800 |
| Earnings Timestamp End | 1,790,020,800 |
| Earnings Timestamp Start | 1,790,020,800 |
| Ebitda | -291,548,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -22.228 |
| Enterprise To Revenue | 1,388.315 |
| Enterprise Value | 6,480,656,896 |
| Eps Current Year | -4.19486 |
| Eps Forward | -3.88171 |
| Eps Trailing Twelve Months | -6.08 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 109.9242 |
| Fifty Day Average Change | -23.7042 |
| Fifty Day Average Change Percent | -0.21564132 |
| Fifty Two Week Change Percent | -9.0680895 |
| Fifty Two Week High | 148.83 |
| Fifty Two Week High Change | -62.61 |
| Fifty Two Week High Change Percent | -0.42068133 |
| Fifty Two Week Low | 69.81 |
| Fifty Two Week Low Change | 16.410004 |
| Fifty Two Week Low Change Percent | 0.23506667 |
| Fifty Two Week Range | 69.81 - 148.83 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,697,808,600,000 |
| Float Shares | 62,468,031 |
| Forward Eps | -3.88171 |
| Forward P E | -22.21186 |
| Free Cashflow | -125,898,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 98 |
| Fullday Change | -0.9200058 |
| Fullday Change Percent | -1.0582078 |
| Fullday Price | 86.22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 4,668,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.72358 |
| Implied Shares Outstanding | 87,271,525 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-10-20 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France. |
| Long Name | ABIVAX Société Anonyme |
| Market | us_market |
| Market Cap | 7,524,551,168 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_256839883 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -401,217,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,370,186,155 |
| Number Of Analyst Opinions | 12 |
| Open | 85.92 |
| Operating Cashflow | -197,020,000 |
| Operating Margins | -86.1793 |
| Phone | 33 1 53 83 09 63 |
| Post Market Change | -0.20000458 |
| Post Market Change Percent | -0.23197004 |
| Post Market Price | 86.02 |
| Post Market Time | 1,791,930,557 |
| Previous Close | 86.94 |
| Price Eps Current Year | -20.553726 |
| Price Hint | 2 |
| Price To Book | 16.774315 |
| Price To Sales Trailing12 Months | 1,611.9432 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.792 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.720001 |
| Regular Market Change Percent | -0.828159 |
| Regular Market Day High | 86.845 |
| Regular Market Day Low | 84.51 |
| Regular Market Day Range | 84.51 - 86.845 |
| Regular Market Open | 85.92 |
| Regular Market Previous Close | 86.94 |
| Regular Market Price | 86.22 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 992,713 |
| Return On Assets | -0.62882 |
| Return On Equity | -2.52349 |
| Revenue Growth | -0.068 |
| Revenue Per Share | 0.06 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 87,271,525 |
| Shares Percent Shares Out | 0.089099996 |
| Shares Short | 7,776,429 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,962,029 |
| Short Name | Abivax SA |
| Short Percent Of Float | 0.09020001 |
| Short Ratio | 5.73 |
| Source Interval | 15 |
| Symbol | ABVX |
| Target High Price | 181.0 |
| Target Low Price | 142.0 |
| Target Mean Price | 163.58333 |
| Target Median Price | 164.0 |
| Total Cash | 402,383,008 |
| Total Cash Per Share | 5.041 |
| Total Debt | 1,212,000 |
| Total Revenue | 4,668,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 116.85365 |
| Two Hundred Day Average Change | -30.633652 |
| Two Hundred Day Average Change Percent | -0.26215398 |
| Type Disp | Equity |
| Volume | 992,713 |
| Website | https://www.abivax.com |
| Zip | 75,009 |